A- A A+

High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011–2014: missed opportunities for hepatitis C testing.

Enkelmann, J., Gassowski, M., Nielsen, S. et al. 

Harm Reduct J 17, 7 (2020) doi:10.1186/s12954-019-0338-y

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0338-y

Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).

Marcellin F, Di Beo V, Aumaitre H, Mora M, Wittkop L, Duvivier C, Protopopescu C, Lacombe K, Esterle L, Berenger C, Gilbert C, Bouchaud O, Poizot-Martin I, Sogni P, Salmon-Ceron D, Carrieri P; ANRS CO13 HEPAVIH Study Group.

J Hepatol. 2020 Jan 7. pii: S0168-8278(19)30646-4. doi: 10.1016/j.jhep.2019.10.019. 

https://www.journal-of-hepatology.eu/article/S0168-8278(19)30646-4/fulltext

Wechselwirkungen mit HCV-DAA-Medikamenten – Update on hep-druginteractions.org

We have added some new comedications to the interaction checker, at the request of some of our users. You can now look up interactions with alcohol, cannabidiol (CBD), carfentanil, clofazimine, heroin and mesna. (The University of Liverpool’s HEP Drug Interactions Checker, UK, 06.01.2020)

https://hep-druginteractions.org/checker

Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.

Krauth C, Rossol S, Ortsäter G, Kautz A, Krüger K, Herder B, Stahmeyer JT.

BMC Infect Dis. 2019 Dec 2;19(1):1019. doi: 10.1186/s12879-019-4524-z.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889318/

An Investigation of the Side Effects, Patient Feedback, and Physiological Changes Associated with Direct-Acting Antiviral Therapy for Hepatitis C.

Wu PS, Chang TS, Lu SN, Su HJ, Chang SZ, Hsu CW, Chen MY.

Int J Environ Res Public Health. 2019 Dec 7;16(24). pii: E4981. doi: 10.3390/ijerph16244981.

https://www.mdpi.com/1660-4601/16/24/4981

Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves.

El Kassas M, Tawheed A, Eltabbakh M, Kaseb A.

J Hepatocell Carcinoma. 2019 Nov 19;6:183-191. doi: 10.2147/JHC.S206668. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879003/

Dynamic modeling of hepatitis C transmission among people who inject drugs.

Stocks T, Martin LJ, Kühlmann-Berenzon S, Britton T.

Epidemics. 2019 Dec 11;30:100378. doi: 10.1016/j.epidem.2019.100378.

https://www.sciencedirect.com/science/article/pii/S1755436518301555?via%3Dihub

Overview of hepatitis C infection, molecular biology, and new treatment.

Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S.

J Infect Public Health. 2019 Dec 20. pii: S1876-0341(19)30356-9. doi: 10.1016/j.jiph.2019.11.015.

https://www.sciencedirect.com/science/article/pii/S1876034119303569?via%3Dihub

High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.

Semá Baltazar C, Horth R, Boothe M, Sathane I, Young P, Chitsondzo Langa D, Condula M, Ricardo H, Dengo Baloi L, Cummings B, Schaad N, Gouveia L, Teodoro E, Raymond HF.

BMC Infect Dis. 2019 Dec 2;19(1):1022. doi: 10.1186/s12879-019-4655-2.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889180/

From peer-based to peer-led: redefining the role of peers across the hepatitis C care pathway: HepCare Europe.

Surey J, Menezes D, Francis M, Gibbons J, Sultan B, Miah A, Abubakar I, Story A.

J Antimicrob Chemother. 2019 Nov 1;74(Supplement_5):v17-v23. doi: 10.1093/jac/dkz452.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883389/

Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.

Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua N, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J.

J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30699-3. doi: 10.1016/j.jhep.2019.11.012. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31785345

Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients.

Shousha HI, Saad Y, Saleh DA, Dabes H, Alserafy M, ElShazly Y, Said M.

Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001612. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31789947

A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection.

Proeschold-Bell RJ, Evon DM, Yao J, Niedzwiecki D, Makarushka C, Keefe KA, Patkar AA, Mannelli P, Garbutt JC, Wong JB, Wilder JM, Datta SK, Hodge T, Naggie S, Fried MW, Muir AJ.

Hepatology. 2019 Dec 5. doi: 10.1002/hep.31058. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31803945

Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

Ghany MG, Marks KM, Morgan TR, Wyles DL, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Feld JJ, Gordon SC, Heller T, Jhaveri RR, Jonas MM, Kiser JJ, Linas BP, Lo Re V, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Spradling P, Terrault NA, Trooskin SB, Verna EC, Wong JB, Woolley AE, Workowski KA.

Hepatology. 2019 Dec 9. doi: 10.1002/hep.31060. 

https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.31060

Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review.

Babiker A, Hassan M, Muhammed S, Taylor G, Poonia B, Shah A, Bagchi S.

Clin Cardiol. 2019 Nov 30. doi: 10.1002/clc.23299.

https://onlinelibrary.wiley.com/doi/full/10.1002/clc.23299

HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges?

Rockstroh JK, Yazdanpanah Y.

J Antimicrob Chemother. 2019 Nov 1;74(Supplement_5):v2-v4. doi: 10.1093/jac/dkz447. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883388/

Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study.

Liu Y, Zou X, Chen W, Gong C, Ling L.

Int J Environ Res Public Health. 2019 Nov 12;16(22). pii: E4436. doi: 10.3390/ijerph16224436.

https://www.mdpi.com/1660-4601/16/22/4436

Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).

Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA; INTRO-HCV Study Group.

BMC Infect Dis. 2019 Nov 8;19(1):943. doi: 10.1186/s12879-019-4598-7.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839172/

Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?

Zuckerman AD, Douglas A, Whelchel K, Choi L, DeClercq J, Chastain CA.

PLoS One. 2019 Nov 21;14(11):e0225434. doi: 10.1371/journal.pone.0225434.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0225434

Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients.

Ing Lorenzini K, Girardin F.

Liver Int. 2019 Oct 26. doi: 10.1111/liv.14283. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31654604

The Impact of Hepatitis C Virus Infection on Buprenorphine Dose in Pregnancy.

McDowell ML, Tonismae TR, Slaven JE, Abernathy MP, Shanks AL, Benjamin TD, Quinney SK.

Am J Perinatol. 2019 Oct 26. doi: 10.1055/s-0039-1698838.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31655490

National Trends in Hepatitis C Infection by Opioid Use Disorder Status Among Pregnant Women at Delivery Hospitalization - United States, 2000-2015.

Ko JY, Haight SC, Schillie SF, Bohm MK, Dietz PM.

MMWR Morb Mortal Wkly Rep. 2019 Oct 4;68(39):833-838. doi: 10.15585/mmwr.mm6839a1.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776372/

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.

Shili-Masmoudi S, Sogni P, de Ledinghen V, Esterle L, Valantin M-A, Poizot-Martin I, et al. (2019) 

PLoS ONE 14(1): e0211286. doi.org/10.1371/journal.pone.0211286

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211286

Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data.

Yen Y-H, Chen C-H, Hung C-H, Wang J-H, Lu S-N, Kee K-M, et al. (2019) 

PLoS ONE 14(10): e0222605. doi.org/10.1371/journal.pone.0222605

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222605

Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals.

Garcia A, Moore Boffi S, Gayet-Ageron A, Vernaz N (2019) 

PLoS ONE 14(10): e0223649. doi.org/10.1371/journal.pone.0223649

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0223649

Chronic HCV infection and neuropsychiatric dysfunction.

Fortini I, Arouca EMG, Tengam FM, Nitrini R.

eNeurologicalSci. 2019 Sep 5;17:100206. doi: 10.1016/j.ensci.2019.100206. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806448/

Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS‐FANTASIO study),

Barre, T., Marcellin, F., Di Beo, V., Delorme, J., Rojas Rojas, T., Mathurin, P., Protopopescu, C., Bailly, F., Coste, M., Authier, N., Carrieri, M. P., and Rolland, B. ( 2019) 

Addiction. doi.org/10.1111/add.14820. 

https://onlinelibrary.wiley.com/doi/full/10.1111/add.14820

Rapid point-of-care HCV RNA quantification in capillary whole blood for diagnosing chronic HCV infection, monitoring treatment and detecting reinfection.

Bregenzer A, Warmann N, Ottiger C, Fux CA.

Swiss Med Wkly. 2019 Oct 27;149:w20137. doi: 10.4414/smw.2019.20137.

https://smw.ch/article/doi/smw.2019.20137

Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study.

Schulte B, Schmidt CS, Strada L, Rosenkranz M, Schäfer I, Verthein U, Reimer J.

Clin Infect Dis. 2019 Oct 21. pii: ciz661. doi: 10.1093/cid/ciz661. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31631215

Launch of Injecting Drug User Implementation Tool Training Manual 

INPUD is very excited to launch the Injecting Drug User Implementation Tool Training Manual and accompanying slides.

Developed jointly by UNODC and INPUD, in collaboration with other partners, the guidance document Implementing Comprehensive HIV Programmes with People who Inject Drugs: Practical Approaches from Collaborative Interventions – otherwise known as the Injecting Drug User Implementation Tool (IDUIT) – was published in 2016.  It describes how to implement effective programmes and services for HIV and HCV prevention interventions for and with people who inject drugs.

The training manual is designed to support the roll-out of the IDUIT through capacity building at regional, country or local level. It has been developed to facilitate the work of trainers in organising and delivering training and workshops on the IDUIT to communities of people who use drugs to help them serve their own community in line with the evidence based and human rights-based approaches outlined in the IDUIT, and to interact with a wide range of governmental and non-governmental organisations, including public health and drug policy makers, and harm reduction and HIV programme managers and staff. (INPUD - International Network of People who Use Drugs, Oktober 2019)

https://www.inpud.net/en/launch-injecting-drug-user-implementation-tool-training-manual